

Experience

Partner, New York

Intellectual Property and Technology



T: 212.735.3056
F: 917.777.3056
matthew.zisk@skadden.com

Licensing, Asset Sales and Collaborations

Clean Tech and Renewable Energy

- CF Industries in its in-licensing of coal and pet-coke gasification, and controlled-release fertilizer manufacturing and composition technologies;
- Demeter Systems LLC in its out-licensing of clean coal treatment technology;
- E. I. du Pont de Nemours and Company in its in-licensing of a thermal technology for biomass conversion and in the operation of its licensing arrangements with Invista;
- Global Opportunities Investments LLC and its wholly owned subsidiary Activeion Cleaning Solutions LLC in in-licensing and counseling matters related to chemical-free cleaning and sanitization technologies; and
- Viridis Waste Control in its out-licensing of its landfill bioreactor technology to municipal waste authorities.

Medical Device and Diagnostics

- Caris Diagnostics, Inc. in various in-licensing related to its molecular and anatomical diagnostics businesses;
- Deep Breeze, Ltd. in out-licensing its acoustic diagnostics technologies to GE Healthcare;
- Kinetic Concepts, Inc. in in-licensing technologies related to its wound-healing and tissue implants businesses;
- mNEMOSCIENCE GmbH in out-licensing its shape-memory polymer technology to Aporo Biosciences; and
- Sober Steering Sensor, LLC, in its development and licensing of blood alcohol measurement and automobile ignition interlock technology;

Pharmaceuticals

- Collagen Matrix in a majority investment by Metalmark Capital;
- Endo Pharmaceuticals, Inc. in various strategic collaborations and acquisitions, recently including its offer to acquire Salix Pharmaceuticals, its sale of its Men's Health Business to Boston Scientific, its acquisition of NuPathe and various financing, strategic alliance and licensing arrangements for pharmaceutical products;
- Gilead Sciences in its acquisition of Phenex and in various financing and licensing matters;
- Horizon Pharma in its acquisition of Pennsaid 2.5%;
- Hospira in its acquisition by Pfizer;
- Human Genome Sciences in its acquisition by GSK;
- Mylan Laboratories in its acquisition of Agila Specialties;
- NPS Pharmaceuticals in its acquisition by Shire;
- Shionogi & Co. Ltd. in its restructuring of its strategic alliance with GSK and Pfizer;

Matthew B. Zisk

Continued

-
- Valeant Pharmaceuticals in various strategic collaborations and acquisitions, including its acquisition of dermatology product businesses from Johnson & Johnson and Sanofi, its acquisition of Targretin from Eisai, its strategic arrangements with Meda AB, its acquisitions of Eyetech and Orapharma, and various other tax structuring, financing, strategic licensing and product acquisitions;
 - Viropharma in its merger into Shire;
 - various biopharmaceutical companies, including Algeta, BZL Biologics, Genus Oncology, Relmada Therapeutics and Vital Matters in their IP estates, structuring and strategic alliance matters; and
 - various underwriters and issuers in in their initial public offerings, including those related to Enzymotech, Evogene, Foamix, Luminess, Macrocure, Mediwound, and Prosensa.

Mergers and Acquisitions

- Abbott Laboratories in its attempted sale of its diagnostics business to GE Healthcare;
- Advanced Medical Optics in its attempted acquisition of Bausch & Lomb;
- BioVeris Corp. in its merger with Roche;
- BNP Paribas as lead arranger for \$200 million financing for an acquisition of Quadriga and related entities;
- Credit Suisse in arranging secured bank financing for the acquisition by a subsidiary of Onex Corporation of Kodak's health care business;
- Daimler in its sale of an 80 percent interest in Chrysler to Cerberus Capital Management L.P.;
- Dubai Aerospace Enterprise in its acquisitions and sales of major aviation businesses in the United States;
- Endo Pharmaceuticals in its acquisition of Indevus Pharmaceuticals;
- Kinetic Concepts, Inc. in its acquisition of LifeCell, Inc.;
- LeadAmerica in its acquisition of National Education Council, Inc.;
- Littlejohn in its purchase from ITT of a switch business and in its related operation of CoActive Technologies;

- Omrix in its merger with Johnson & Johnson; and
- Valeant Pharmaceuticals International in the sale of its European businesses to Meda AB.

Renewable Energy Investments

- a consortium of investors in a \$140 million equity financing of SolarReserve;
- Citi Sustainable Developments Investments in investments in solar and materials technologies companies;
- Ecofin in investments in solar technology companies;
- Enertech Capital in an investment in a solar technology company;
- Good Energies, Inc. in investments in companies developing solar and biofuel technologies, building control and HVAC systems, and low carbon-impact materials; and
- Hudson Clean Energy Partners in an investment in a solar technology company.

Spin Outs and Corporate Finance and Restructuring

- Allied Bank Limited as a lender in a senior secured debt financing for Douglas Dynamics;
- Bear Stearns as financial advisors to Clinical Data, Inc. in an equity offering;
- Bentley Pharmaceutical, Inc. in its spin out of its innovator pharmaceuticals business;
- The Broad Institute in its separation from Harvard University and the Massachusetts Institute of Technology;
- Delphi in relation to its restructuring;
- Enzon in its attempted spin out of its biopharmaceuticals business;
- Equity Group Investors in its investment in Middlebrook Pharmaceuticals; and
- Fortress Drawbridge in funding of Iroko Pharmaceuticals and related acquisitions of products.